The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Multiple functional domains of the heparin molecule.
Open accessAbstract
Affinity-fractionated porcine heparin was randomly scissioned by chemical techniques to give hexasaccharides, octasaccharides, decasaccharides, and mucopolysaccharide fragments of approximately 14 residues and approximately 16 residues that were able to complex with the protease inhibitor. Direct measurements of the kinetic behavior of the hexasaccharides, octasaccharides, and decasaccharides showed that these fractions greatly enhanced the rate of Factor Xa inactivation by antithrombin. Indeed, these species exhibited specific molar activities that ranged from 6.9% (hexaccharide) to 60.9% (decasaccharide) of that of the heparin fragment of approximately 16 residues. However, these oligosaccharides exhibited essentially no ability to accelerate thrombin-antithrombin interactions. The avidity of the hexasaccharides, octasaccharides, and decasaccharides for the protease inhibitor increased as a function of size with the respective dissociation constants ranging from 5.5 X 10(-6) M to 2.9 X 10(-7) M. These data suggest that the region of the heparin molecule needed for catalyzing Factor Xa-antithrombin interaction is intimately related to the antithrombin binding domain. The smallest complex carbohydrate fragment that accelerated the inactivation of thrombin by antithrombin had approximately 14 residues. This fraction had an avidity for the protease inhibitor of 2.8 X 10(-7) M and specific molar activities of 140 units per mumol (thrombin neutralization) and 460 units per mumol (factor Xa inactivation). The largest heparin fragment examined contained approximately 16 residues. This fraction had an avidity for antithrombin of 2.4 X 10(-7) M and specific molar activities of 500 units per mumol (thrombin neutralization) and 560 units per mumol (Factor Xa inactivation). Detailed kinetic analyses showed that these two species are able to directly activate antithrombin to the same extent with respect to thrombin inhibition. However, the larger mucopolysaccharide fragment is also capable of approximating free enzyme with protease inhibitor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure of the antithrombin-binding site in heparin.
Lindahl, U., Bäckström, G., Höök, M., Thunberg, L., Fransson, L. A., & Linker, A. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.7.3198 · Cited by 368
Correlation between structure and function of heparin
Rosenberg, R. D., & Lam, L. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.3.1218 · Cited by 281
Self-citation
Cited by
Hirsh, J., Warkentin, T. E., Shaughnessy, S. G., Anand, S. S., Halperin, J. L., Raschke, R., Granger, C., Ohman, E. M., & Dalen, J. E. (2001) · Chest · doi:10.1378/chest.119.1_suppl.64s · Cited by 1,580
Garcia, D. A., Baglin, T. P., Weitz, J. I., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2291 · Cited by 1,091
Heparin and Low-Molecular-Weight Heparin
Hirsh, J., Warkentin, T. E., Raschke, R., Granger, C., Ohman, E. M., & Dalen, J. E. (1998) · Chest · doi:10.1378/chest.114.5_supplement.489s · Cited by 1,031
Heparin and Low-Molecular-Weight Heparin
Hirsh, J., & Raschke, R. (2004) · Chest · doi:10.1378/chest.126.3_suppl.188s · Cited by 971
Oates, J. A., Wood, A. J. J., & Hirsh, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242206 · Cited by 830
Hirsh, J., Bauer, K. A., Donati, M. B., Gould, M., Samama, M. M., & Weitz, J. I. (2008) · Chest · doi:10.1378/chest.08-0689 · Cited by 755
Hirsh, J., Anand, S. S., Halperin, J. L., & Fuster, V. (2001) · Circulation · doi:10.1161/01.cir.103.24.2994 · Cited by 565
Hirsh, J., Dalen, J. E., Deykin, D., & Toller, L. (1992) · Chest · doi:10.1378/chest.102.4_supplement.337s · Cited by 558
Mechanism of the anticoagulant action of heparin
Bj�rk, I., & Lindahl, U. (1982) · Molecular and Cellular Biochemistry · doi:10.1007/bf00421226 · Cited by 494
A Synthetic Antithrombin III Binding Pentasaccharide Is Now a Drug! What Comes Next?
Petitou, M., & van Boeckel, C. A. A. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200300640 · Cited by 485
Olson, S. T., Björk, I., Sheffer, R., Craig, P. A., Shore, J. D., & Choay, J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42309-5 · Cited by 470
Further characterization of the antithrombin-binding sequence in heparin
Thunberg, L., Bäckström, G., & Lindahl, U. (1982) · Carbohydrate Research · doi:10.1016/s0008-6215(00)81050-2 · Cited by 455
Activation of heparin cofactor II by dermatan sulfate.
Tollefsen, D. M., Pestka, C. A., & Monafo, W. J. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32276-2 · Cited by 436
Structure and Biological Activity of Heparin
Casu, B. (1985) · Advances in Carbohydrate Chemistry and Biochemistry · doi:10.1016/s0065-2318(08)60067-0 · Cited by 428
Glycosaminoglycans and the regulation of blood coagulation
Bourin, M. C., & Lindahl, U. (1993) · Biochemical Journal · doi:10.1042/bj2890313 · Cited by 419
Hirsh, J., Raschke, C. R., Warkentin, T. E., Dalen, J. E., Deykin, D., & Poller, L. (1995) · Chest · doi:10.1378/chest.108.4_supplement.258s · Cited by 394
Chen, L.-J., & Yang, H.-B. (2018) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00317 · Cited by 390
Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4
Lane, D. A., Denton, J., Flynn, A. M., Thunberg, L., & Lindahl, U. (1984) · Biochemical Journal · doi:10.1042/bj2180725 · Cited by 342
Extension and structural variability of the antithrombin-binding sequence in heparin.
Lindahl, U., Thunberg, L., Bäckström, G., Riesenfeld, J., Nordling, K., & Björk, I. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)90755-6 · Cited by 340
Synthesis of thrombin-inhibiting heparin mimetics without side effects
Petitou, M., Hérault, J.-P., Bernat, A., Driguez, P.-A., Duchaussoy, P., Lormeau, J.-C., & Herbert, J.-M. (1999) · Nature · doi:10.1038/18877 · Cited by 326
Chen, L.-J., Ren, Y.-Y., Wu, N.-W., Sun, B., Ma, J.-Q., Zhang, L., Tan, H., Liu, M., Li, X., & Yang, H.-B. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b06565 · Cited by 306
Heparin: Past, Present, and Future
Oduah, E., Linhardt, R., & Sharfstein, S. (2016) · Pharmaceuticals · doi:10.3390/ph9030038 · Cited by 281
Natural anticoagulant mechanisms.
Rosenberg, R. D., & Rosenberg, J. S. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111389 · Cited by 258
Self-citationContribution of monosaccharide residues in heparin binding to antithrombin III
Atha, D. H., Lormeau, J. C., Petitou, M., Rosenberg, R. D., & Choay, J. (1985) · Biochemistry · doi:10.1021/bi00344a063 · Cited by 255
Self-citationDanielsson, A., Raub, E., Lindahl, U., & Björk, I. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)66735-3 · Cited by 252
Metadata
- Authors
- Oosta, G. M., Gardner, W. T., Beeler, D. L., & Rosenberg, R. D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1981-02
- Volume
- 78
- Issue
- 2
- Pages
- 829-833
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2004746423
- Cited by
- 187
- References
- 2
- FWCI
- 11.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.